Merck reported second quarter revenue of $16.61 billion, beating analyst estimates of $16.27 billion, while adjusted EPS came in at negative $0.13 versus expectations of negative $0.26. The company slightly lifted its full-year revenue guidance to $66.8 billion at the midpoint from $66.4 billion, but lowered its full-year adjusted EPS guidance to $2.71 at the midpoint, a 46.9% decrease. During the earnings call, analysts questioned management on topics including a potential broad sac-TMT plus pembrolizumab trial in first-line lung cancer, TL1A activity compared to TNF inhibitors, LIPFENDRA commercial adoption, the ulcerative colitis program, and oral PCSK9 market expansion. Merck currently trades at $129.75, up from $127.77 just before the earnings.
Merck & Company IncQ2 revenue beat and raised full-year revenue guidance, though EPS guidance cut.
Merck KGaA